SavedAdd your journal

Journals / Anatolian Current Medical Journal / 2026 / Volume: 4 Issue: 3

Cardiac effects of Sugammadex and Rocuronium combination in rats: experimental study

Mevlüt Doğukan(ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4890-758X
Nezir Yılmaz(Adıyaman Eğitim ve Araştırma Hastanesi)0000-0002-4351-6256
Ebru Annaç(ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-9726-5846
Zümrüt Doğan(ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7131-2317
Fatih Üçkardeş(ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-0677-7606
Öznur Uludag(ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-6017-5836
Pages
—
Publication Date
2022-07-26
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although sugammadex and sugammadex-rocuronıum complex cause biochemical and histopathological effect on the heart tissue, there were no irreversible histopathologic changes and no significant biochemical difference found in this study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this experimental study, it was aimed to examine the effects of rocuronium and sugammadex complex on cardiac muscle cells in rats histopathologically and biochemically.
📊
Key Findings & Data:Matherial and Method: 32 adult Sprague-Dawley male rats were divided into four groups with 8 in each group.
💡
Conclusion & Impact:Conclusion: Although sugammadex and sugammadex-rocuronıum complex cause biochemical and histopathological effect on the heart tissue, there were no irreversible histopathologic changes and no significant biochemical difference found in this study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sugammadex · rocuronium · cardiac muscle

Abstract

Aim: In this experimental study, it was aimed to examine the effects of rocuronium and sugammadex complex on cardiac muscle cells in rats histopathologically and biochemically. Matherial and Method: 32 adult Sprague-Dawley male rats were divided into four groups with 8 in each group. Group 1 consisted of animals that did not undergo surgical treatment. Group 2 received a volume equivalent to 16 mg/kg sugammadex with 0.9% intravenous saline. Group 3 received 16 mg/kg of intravenous sugammadex. Group 4, 1 mg/kg intravenous rocuronium and 16 mg/kg intravenous sugammadex were administered to rats. After the procedure completed GSH and MDA level evaluated biochemically; and heart tissue evaluated histopathologically. Results: In group 4, connective tissue edema between muscle fibers was observed to be significantly increased, vessel dilatation and hemorrhagic areas were observed. Groups 3 and 4 were found to cause an increase in GSH level when compared to Groups 1 and 2, and a decrease in MDA level in these two groups compared to the others. Conclusion: Although sugammadex and sugammadex-rocuronıum complex cause biochemical and histopathological effect on the heart tissue, there were no irreversible histopathologic changes and no significant biochemical difference found in this study.

🔖

Cite This Article

Doğukan, M., Yılmaz, N., Annaç, E., Doğan, Z., Üçkardeş, F., Uludag, Ö. (2022). Cardiac effects of Sugammadex and Rocuronium combination in rats: experimental study. Anatolian Current Medical Journal, Volume: 4 Issue: 3. https://doi.org/10.38053/acmj.1088069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (24)

  1. Fisher DM. Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm 1999; 56: 4–9.
  2. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: Reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006; 96: 201-6.
  3. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemi-cal encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70.
  4. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth 2016; 35: 1-12.
  5. Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018; 73: 631-41.
  6. Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al.A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia 2015; 70: 1441-52.
  7. Won YJ, Lim BG, Lee DK, Kim H, Kong MH, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e4678.
  8. Lee W. The potential risks of sugammadex. Anesth Pain Med 2019; 14: 117-22.
  9. Uludağ Ö. Effect of sugammadex and rocuronium combination on cranial neurotoxicity in rats: Experimental study. KafkasUniv Vet Fak Derg 2019; 25: 793-9.
  10. Miller MA, Zachary JF. Mechanisms and morphology of cellular injury, adaptation, and death. In: Pathologic Basis of Veterinary Disease. Elsevier; 2017. p. 2-43.e19.
  11. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissue by TBA test. AnalBiochem1978; 86: 271-8.
  12. Elman GL. Tissue sulphydryl groups. Arch Biochem Biophys 1959; 82: 70-7.
  13. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaest 2008; 100: 373–9.
  14. De Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: A multi center, dose-finding and safety study. Anesthesiology 2007; 107: 239–44.
  15. Osaka Y, Shimada N, Satou M, et al. A case of atrioventricular block (Wenckebach type) induced by sugammadex. J Anesth 2012; 26: 627–8.
  16. Kokki M, Ali M, Turunen M, Kokki H. Suspected unexpected adverse effect of sugammadex: Hypotension. Eur J Clin Pharmacol 2012; 68: 899–900.
  17. Bhavani SS. Severe bradycardia and asystole after sugammadex. Br J Anesth 2018; 121: 95–6.
  18. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia 2014; 69: 1251–7.
  19. Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 2009; 26: 874-84.
  20. de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig 2010; 30: 599–611.
  21. Bostan H, Kalkan Y, Tomak Y, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex and resulting histopathological effects in rat kidneys. Ren Fail 2011; 33: 1019-24.
  22. Kalkan Y, Bostan H, Tumkaya L, et al.The effect of rocuronium, sugammadex, and their combination on cardiac muscle and diaphragmatic skeletal muscle cells. J Anesth 2012; 26: 870-7.
  23. Tercan M, Yılmaz İnal F, Seneldir H, Kocoglu H. Nephroprotective efficacy of sugammadex in ischemia-reperfusion injury: an experimental study in a rat model. Cureus. 2021; 13: e15726.
  24. Ozbilgin S, Yılmaz O, Ergur BU, et al. Effectiveness of sugammadex for cerebral ischemia/reperfusion injury. Kaohsiung J Med Sci 2016; 32: 292-301.